News

Two university professors have each been awarded $25,000 small research grants from the Foundation for Sarcoidosis Research (FSR) to pursue projects aimed at improving outcomes for people with sarcoidosis. Researcher Maneesh Bhargava, MD, PhD, of the University of Minnesota, will use the grant to focus on inflammation in…

A new grant program worth up to $3.5 million, from the Ann Theodore Foundation, is seeking researchers in the U.S. who are working to advance knowledge and understanding of sarcoidosis. The Milken Institute, a nonprofit think tank, is accepting applications from American research institutions for the Ann Theodore…

The Foundation for Sarcoidosis Research (FSR) announced its newest initiative this month, the African American Women & Sarcoidosis National Campaign, to bring awareness to how this group is disproportionately affected by the disease and to educate people living with the disorder. African American women are three times more…

White women with sarcoidosis and multiorgan involvement may be at a higher risk of hypothyroidism, or low thyroid gland activity, than other people with the overactive immune system disorder, according to a study of more than 3,800 patients in the U.S. In fact, hypothyroidism — which is significantly…

A DNA sequencing technology called next-generation sequencing (NGS) may be used to detect tuberculosis (TB) rapidly and accurately — which could help in distinguishing it from sarcoidosis, a study suggests. While tuberculosis and sarcoidosis share many symptoms, the therapies for the two diseases differ greatly, according to researchers.

Football and science seem to be disparate fields of play at first glance, but the nonprofit Uplifting Athletes is finding common ground by leveraging the popularity of college gridiron games to fund research for rare diseases. Its nearly two dozen chapters — representing college football teams across the nation…

aTyr Pharma’s experimental therapy ATYR1923 safely and effectively improves lung function and reduces symptoms in adults with pulmonary sarcoidosis, while lowering the need for oral corticosteroids, top-line data from a Phase 1b/2a clinical trial show. Notably, while all three tested therapy doses were well-tolerated, greater clinically meaningful…

A Phase 2 clinical trial investigating the inhaled sarcoidosis therapy aviptadil — also known as RLF-100, and designed to block inflammation in the lungs — has been cleared to start in Germany. The clearance by the German medical regulatory authority Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) was given to…

aTyr Pharma has announced a collaboration with The Ohio State University (OSU) to conduct cell culture studies seeking to identify potential biomarkers that can predict ATYR1923’s therapeutic effectiveness in people with pulmonary sarcoidosis. The research, which extends previous proof-of-concept findings, will delineate the pathways involved in sarcoid granuloma formation…

The U.S. Food and Drug Administration has granted orphan drug designation to RLF-100 (aviptadil), Relief Therapeutics’ investigational inhaled therapy for sarcoidosis. Such status is given to treatment candidates with the potential to be safe and effective in rare diseases — defined in the U.S. as those affecting fewer…